RAN-CARVEDILOL TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
06-10-2016
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CARVEDILOL
제공처:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC 코드:
C07AG02
INN (International Name):
CARVEDILOL
복용량:
25MG
약제 형태:
TABLET
구성:
CARVEDILOL 25MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
BETA-ADRENERGIC BLOCKING AGENTS
제품 요약:
Active ingredient group (AIG) number: 0122683001; AHFS:
승인 상태:
CANCELLED POST MARKET
승인 날짜:
2022-09-16
제품 특성 요약
PRODUCT MONOGRAPH
PR
RAN™-CARVEDILOL
Carvedilol Tablets, House Standard
3.125, 6.25, 12.5 and 25 mg
CONGESTIVE HEART FAILURE AGENT
Ranbaxy Pharmaceuticals Canada Inc. DATE OF REVISION:
126 East Drive SEPTEMBER 14, 2016
Brampton, Ontario
L4W 0A5
Submission Control No: 197425
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_ _
_RAN-CARVEDILOL Product Monograph _
_ _
_Page 2 of 38 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
.............................................................................................
전체 문서 읽기
